L&T to make largest BESS site co-located with solar energy generation in Bihar
Larsen & Tourbo has received an EPC contract to develop a grid-connected 116 MWac Solar Photovoltaic (PV) plant at Kajra, Lakhisarai district in Bihar, the company announced on Monday.The company has categorised the order under 'significant' order implying the order value between Rs 1,000 to Rs 2,500.
This plant will be integrated with a 241 MWh Battery Energy Storage System (BESS), aiming to make Lakhisarai in Bihar the largest energy storage site co-located with solar energy generation.
This order marks the extension of the earlier phase, taking the total co-located storage capacity of the renewable generation site at Lakhisarai to 495 MWh — the largest such project awarded by a state utility in India, the company said in a stock exchange filing.
Shares of Larsen & Toubro Ltd. were trading at Rs 3626.00 per unit as on August 4, 11:23 PM on BSE.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
10 minutes ago
- Indian Express
Tata Sons-backed Tata Capital Ltd files for IPO
Tata Sons-backed non-banking financial company (NBFC), Tata Capital Ltd, filed draft papers on Monday for an initial public offering (IPO). Tata Capital's IPO consists of a combination of fresh issuance and an offer for sale (OFS), amounting to approximately 47.58 crore equity shares. The company will be issuing up to 21 crore new shares and the existing shareholders are looking to offload up to 26.58 crore shares. Tata Sons Private Ltd, the promoter of the company, is planning to sell up to 23 crore shares in the IPO, while International Finance Corporation (IFC) has proposed to sell up to 3.58 crore shares. The issue size is estimated at around Rs 17,000 crore, as per Prime Database. The shares will be issued at a face value of Rs 10 per share. The company will use the proceeds from the fresh issue to augment its tier-1 capital base to meet its future capital requirement, including onward lending. Tata Capital is the third largest diversified NBFC in the country. The Reserve Bank of India has classified it as a systemically important NBFC, which requires stricter regulatory adherence. As per the RBI regulations, Tata Capital is required to be listed by the end of September. Tata Capital, the flagship financial services company of the Tata Group, is a subsidiary of Tata Sons Private Limited. It is primarily engaged in the lending business which comprises retail finance, SME finance and corporate finance. Tata Capital's consolidated book size increased to Rs 2,21,950.37 crore as at March 31, 2025 from Rs 1,57,760.55 crore as at March 31, 2024. During FY25, it recorded consolidated total income of Rs 28,369.87 crore as against Rs 18,198.38 crore in FY24, an increase of about 55.89 per cent. On a standalone basis, Tata Capital's recorded gross income of Rs 21,940.08 crore in FY2024-25, compared to Rs 13,309.11 crore in FY24. Profit after tax during the year was Rs 2,594.28 crore as against Rs 2,492.45 crore.
Hindustan Times
10 minutes ago
- Hindustan Times
Boeing defense union strikes for first time in almost 30 years
Workers at Boeing Co.'s St. Louis-area defense factories are striking for the first time in almost three decades after union members rejected the company's modified contract offer. A worker pickets outside the Boeing Defense, Space & Security facility in Berkeley, Missouri, US, on Monday, Aug. 4, 2025.(Bloomberg) About 3,200 machinists walked off the job around midnight after members voted down a deal that would have raised wages by 20% and boosted retirement contributions. The union last went on strike in 1996, with the stoppage lasting 99 days. 'IAM District 837 members have spoken loud and clear, they deserve a contract that reflects their skill, dedication, and the critical role they play in our nation's defense,' Tom Boelling, the union local's top official, said in a statement ahead of the deadline. The labor action will amplify financial pressure on Boeing's defense and space division, which generates almost a third of the company's revenue. At the same time, the operation that's now gone on strike is far smaller than the civil aircraft business that was severely affected late last year by a walkout, which brought manufacturing in the Seattle area to a standstill for weeks and contributed to Boeing selling equity worth almost $24 billion. 'We are prepared for a strike and have fully implemented our contingency plan to ensure our non-striking workforce can continue supporting our customers,' Dan Gillian, a Boeing vice president and senior St. Louis site executive, said in a statement. Union members build fighter aircraft such as the F-15, the T-7 training jet, missiles and munitions. They also manufacture components for Boeing's 777X commercial jets. In March, Boeing won a contract to design and build the US's next-generation stealth fighter jet, beating out rival Lockheed Martin Corp. for the multibillion dollar program dubbed the F-47. Boeing's defense business was profitable for a second consecutive quarter, the company said last month, as it avoided charges that long dogged the business. The company also managed to improve the performance of fixed-price development programs responsible for the worst of previous overruns. There's been a recent groundswell of activism at aerospace manufacturers, with unions gaining leverage amid shortages of highly skilled mechanics. Machinists walked off the job for three weeks at Pratt & Whitney this year, contributing to engine shortages at planemaker Airbus SE. Boeing's commercial factories were shut down by striking workers for two months in late 2024. Boeing Chief Executive Officer Kelly Ortberg downplayed the potential fallout from a strike during the company's July 29 earnings call. 'The order of magnitude of this is much, much less than what we saw last fall,' Ortberg said, noting that the St. Louis union is about 1/10 the size of the Seattle-based union that struck last fall. 'I wouldn't worry too much about the implications of the strike. We'll manage our way through that.' Boeing had crafted its latest offer to address concerns raised by members of International Association of Machinists and Aerospace Workers Local 837 after they rejected its initial proposal last week, Gillian told reporters on July 31. Boeing's proposal to district members would see average wages increase to $102,600 from $75,000 for IAM 837 members. Boeing also eliminated a controversial schedule proposal and revised its 401(k) terms so that workers get the full contribution increase upfront instead of spread over three years. Boeing cautioned that it would withdraw a $5,000 signing bonus and wouldn't offer it again to workers if the contract wasn't ratified on Sunday.
&w=3840&q=100)
Business Standard
10 minutes ago
- Business Standard
Aurobindo Pharma Q1 PAT falls 10% on drop in API sales, US market revenue
Aurobindo Pharma on Monday reported a 10.2% year-on-year (Y-o-Y) drop in consolidated profit after tax (PAT) for the June quarter (Q1 FY26), which stood at Rs 824 crore. The decline was attributed to a drop in sales in its active pharmaceutical ingredients (API) business and the United States (US) market. The Hyderabad-based drugmaker had recorded a net profit of Rs 918 crore in Q1 FY25. The company stated that its API business was affected by pricing pressures and geopolitical tensions, with revenues for the segment falling by 16% Y-o-Y to Rs 916 crore in Q1 FY26. However, the drugmaker recorded a 4% Y-o-Y rise in revenue from operations, reaching Rs 7,868 crore in the June quarter, up from Rs 7,567 crore in Q1 FY25. This increase was primarily driven by a 7.4% Y-o-Y rise in the drugmaker's formulations business revenue, which contributes around 85% of the company's overall revenue. Aurobindo Pharma saw an 18% Y-o-Y revenue growth in European markets, which stood at Rs 2,338 crore, driven by a strong performance across all key markets. Similarly, revenue from growth markets formulations increased by 8.8% Y-o-Y to Rs 772 crore in the June quarter, compared to Rs 709 crore in the same period last year. However, the company's US formulations business, which accounts for 44% of its revenue, saw a marginal 1.9% Y-o-Y dip in sales, from Rs 3,555 crore in Q1 FY25 to Rs 3,488 crore in Q1 FY26. According to the company's regulatory filing, the decline in US revenue was primarily due to a significant reduction in sales of the anti-cancer medication lenalidomide. Commenting on the company's performance, K. Nithyananda Reddy, Vice Chairman and Managing Director of Aurobindo Pharma, said that the company has started FY26 steadily, with its European business maintaining strong growth momentum and the core US business showing resilience despite temporary challenges from destocking and seasonal dynamics. The company announced its results after market hours. On Monday, Aurobindo Pharma's shares rose marginally by 1.04%, ending the day's trade at Rs 1,090.90 apiece on the exchanges.
